Introduction {#section1-1533033818801323}
============

Hypofractionated stereotactic body radiation therapy (SBRT) is commonly prescribed to patients with small-sized primary or oligometastatic lung tumors as a radical and minimally invasive treatment. Stereotactic body radiation therapy has the advantage of administration of a high-dose concentration to the tumor with limited toxicity to normal structures and is therefore well utilized in patients who are medically inoperable owing to poor pulmonary function with chronic lung disease. Stereotactic body radiation therapy is generally safe and has no severe adverse effects in most patients; however, fatal radiation pneumonitis (FRP) occasionally occurs. Fatal radiation pneumonitis shows various patterns of inflammatory shadows inside or outside the irradiated volume and sometimes progresses rapidly to death with accompanying lung edema or infection. Identification of risk factors for FRP after SBRT is important to identify and manage candidates requiring this treatment properly; however, this has not been clarified. Therefore, the purpose of the study was to explore the characteristics, treatment plans, and clinical courses of patients who developed FRP in a Japanese multiinstitutional SBRT study group.

Materials and Methods {#section2-1533033818801323}
=====================

We based our study on a retrospective study design, and received approval from the institutional review board at University of Yamanashi Hospital (approval number 961). Patients who developed FRP after SBRT for primary or metastatic lung cancer were identified from a total of 1789 patients attending 8 institutions that are members of the Japanese multiinstitutional SBRT study group. The SBRT techniques and methods differed among the institutions. The gross target volume (GTV) was delineated on computed tomography (CT) images using a lung window level setting. The clinical target volume (CTV) enlarged the GTV by 0 to 5 mm as judged by the individual radiation oncologist. The internal margin was calculated and set at 2 to 5mm around the CTV according to the individual measurements for respiratory motion determined at each institution. The internal margin caused by respiratory motion was reduced by gating, tracking, the breath-hold technique, or abdominal compression. The planning target volume (PTV) comprised the CTV, a proper internal margin measured for each patient, and a 5 mm safety margin. The irradiated port marginally exceeded the PTV by 3 to 5 mm to secure the surface dose of the PTV. Dose calculation was mainly performed using the Clarkson algorithm with heterogeneity correction. A total dose of 35 to 72.5 Gy (mean, 58.7Gy) at the isocenter in 1 to 10 fractions with a single dose of 7.25 to 35 Gy was administered with 6 MV X-rays. Typical dose/fractionation schedules were 48 Gy in 4 fractions. No chemotherapy regimens were administered before or during radiotherapy. A board-certified thoracic radiologist in each institution examined the CT images of these patients to determine the presence of pulmonary interstitial change. Survival rate was calculated using the Kaplan-Meier method. Statistical difference was calculated with a generalized Wilcoxon test. All statistical analyses were performed using Statview software (SAS, Cary, North Carolina).

Results {#section3-1533033818801323}
=======

Twenty-three of the 1789 patients treated with SBRT for lung cancer (1.3%) developed FRP after SBRT, among whom 18 were men and 5 were women. Detailed characteristics and SBRT of all patients are shown in [Table 1](#table1-1533033818801323){ref-type="table"}. One patient was treated for double lesions simultaneously. It is notable that 14 (73.7%) of 19 cases in which CT could be reviewed showed pulmonary interstitial change. Abnormally high Krebs von den Lungen-6 (KL-6) level was found in 72.2% of the total cases. The median time duration between the start of SBRT and pneumonia symptom appearance was 75 (range: 14-204) days. The median survival time following pneumonia symptom appearance was 53 (range: 4-802) days. Ten (43.5%) of 23 patients died within 1 month of the appearance of pneumonia symptoms. The overall survival (OS) rate for all patients is shown in [Figure 1](#fig1-1533033818801323){ref-type="fig"}. The 6-and 12-month OS rates were 34.8% and 13.0%, respectively.

###### 

Characteristics and Treatment Detail of 23 Patients With Fatal Radiation Pneumonitis.^a^

![](10.1177_1533033818801323-table1)

  ------------------------------------ ------------------------------------------------------
  Age                                  60-92 (median 74) years
  Sex                                  18 male, 5 female
  Disease status                       Primary 17, metastases 4, postoperative recurrence 2
  Tumor size                           15-62 mm (median: 32 mm)
  Number of treated lesion             1:22, 2:1
  Brinkman index                       0-1880 (median 840)
  Pulmonary interstitial change        Positive 14, negative 5, not assigned 4
  Pulmonary emphysema                  Positive 9, negative 10, not assigned 4
  Regular use of steroid before SBRT   Positive 7, negative 15 not assigned 1
  Chronic cardiac disease              Positive 6, negative 15, not assigned 2
  LDH (118-213 IU/L)                   183-795 (median: 255) IU/L
  CRP (0-0.3 mg/dl)                    0.03-2.60 (mean: 0.40) mg/dL
  KL-6 (0-499 U/mLL)                   222-9000 (median: 1320) U/mL
  %VC                                  50-114 (median: 82) %
  FEV 1.0%                             36-135 (median: 83) %
  Size of PTV (mL)                     17-210 (median: 56.5) mL
  Dose of SBRT                         35-75Gy / 1-10 fraction
  BED (α/β = 3 Gy)                     173-433 (median: 240) Gy
  V20 (lung-GTV)\*                     3.8-18.2 (median: 8.0) %
  Mean (lung-GTV) dose                 2.6-12.9 (median: 5.0) Gy
  ------------------------------------ ------------------------------------------------------

Abbreviations: BED, biological effective dose; CRP, C-reactive protein; FEV 1.0%: forced expiratory volume percent in 1 second; GTV, gross target volume; KL-6: Krebs von den Lungen-6; LDH, lactate dehydrogenase; PTV, planning target volume; SBRT, stereotactic body radiation therapy; %VC, percent vital capacity; V20, ratio of the volume receiving 20Gy or more to the normal lung volume.

^a^ Parenthesis: normal range

![Overall survival rate for all patients.](10.1177_1533033818801323-fig1){#fig1-1533033818801323}

The OS rate curves according to the existence of pulmonary interstitial change are shown in [Figure 2](#fig2-1533033818801323){ref-type="fig"}. The 6-month OS rates of patients with and without interstitial change on the CT before SBRT were 50.0% and 14.3%, respectively. The OS rate curves according to the existence of heart disease are shown in [Figure 3](#fig3-1533033818801323){ref-type="fig"}. The 6-month OS rates of patients with and without interstitial change on the CT before SBRT were 16.7% and 46.7%, respectively.

![Overall survival rate according to the existence of pulmonary interstitial change.](10.1177_1533033818801323-fig2){#fig2-1533033818801323}

![Overall survival rate according to the existence of heart disease.](10.1177_1533033818801323-fig3){#fig3-1533033818801323}

There were 4 patients in whom FRP occurred within 2 months after the start of SBRT and who died within 1 month thereof; their characteristics are described in [Table 2](#table2-1533033818801323){ref-type="table"}. Three of these patients had no pulmonary interstitial change before SBRT, but had heart disease. [Figure 4](#fig4-1533033818801323){ref-type="fig"} shows the CT findings of the 5 patients who had pulmonary interstitial change before SBRT. [Figure 5](#fig5-1533033818801323){ref-type="fig"} shows FRP that appeared early in a patient and showed rapid progression.

###### 

Characteristics of the 4 Patients in Whom FRP Occurred Within 2 Months After the Start of SBRT and Resulted in Death in 1 Month.

![](10.1177_1533033818801323-table2)

  Case No.   Duration From SBRT to Onset of FRP, days   Duration From Onset of FRP to Death, days   Age (years)   Sex      Tumor Size (mm)   Brinkman Index   Pulmonary Interstitial Change Before SBRT   Administration of Steroid Before SBRT   Chronis Cardiac Disease   KL-6   %VC    FEV 1.0%   SBRT Dose (Gy/fraction)   V20 (Lung-GV)   MLD, Gy
  ---------- ------------------------------------------ ------------------------------------------- ------------- -------- ----------------- ---------------- ------------------------------------------- --------------------------------------- ------------------------- ------ ------ ---------- ------------------------- --------------- ---------
  2          42                                         4                                           64            Female   30                Unknown          Negative                                    Positive                                Positive                  NA     60%    83.0%      75/10                     20.5%           3.0
  14         44                                         19                                          72            Male     15                300              Negative                                    Positive                                Negative                  835    79%    68.9%      48/4                      6.3%            4.9
  16         56                                         15                                          85            Male     38                800              Positive                                    Negative                                Positive                  989    103%   71.8%      48/4                      6.3%            4.3
  20         42                                         30                                          63            Male     30                840              Negative                                    Negative                                Positive                  NA     65%    73.7%      60/8                      18.2%           9.8

Abbreviation: FEV1.0%: forced expiratory volume percent in one second; FRP, fatal radiation pneumonitis; KL-6, Krebs von den Lungen-6; MLD: mean dose of normal lung; NA: not assigned; SBRT, stereotactic body radiation therapy; %VC: percent vital capacity; V20, ratio of the volume receiving 20Gy or more to the normal lung volume.

![Computed tomography images from 5 patients with fatal radiation pneumonitis in whom pulmonary interstitial change were detected before stereotactic body radiation therapy.](10.1177_1533033818801323-fig4){#fig4-1533033818801323}

![Computed tomography (CT) images from a 64-year-old woman with T2N0M0 adenocarcinoma who developed early fatal radiation pneumonitis that showed rapid progression. The patient had chronic heart failure, and CT performed before stereotactic body radiation therapy (SBRT) showed no pulmonary interstitial change. (A) The tumor shrank (a partial response), but strong dyspnea with diffuse interstitial pneumonitis appeared 40 days after the start of SBRT (B); the patient died 4 days later. The total (normal) lung volume receiving 20 Gy or more (V~20~) was 5.0%, and the mean dose to the normal lung was 3.0 Gy.](10.1177_1533033818801323-fig5){#fig5-1533033818801323}

Discussion {#section4-1533033818801323}
==========

A 2008 survey of Japanese patients who underwent SBRT indicated that treatment-related deaths occurred in 11 (0.46%) of 2390 patients who underwent SBRT for pulmonary lesions.^[@bibr1-1533033818801323]^ In the present study, FRP was observed in 1.3% of the patients investigated; the higher ratio in our study may be attributable to differences in patients' characteristics compared to those in the Japanese survey.

It is important to clarify the mechanisms of FRP as well as its risk factors. Current evidence suggests that numerous factors, as well as various types of lung parenchymal cells, contribute to the pathogenesis of radiation lung damage.^[@bibr2-1533033818801323]^ The progression of radiation-induced damage is a result of the early activation of inflammatory reactions leading to the expression and maintenance of an elevated cytokine cascade.^[@bibr3-1533033818801323]^

With respect to the relationship between radiation pneumonitis and radiotherapy planning, Yamashita *et al* reported a high incidence of FRP (3 of 25 patients) in their early experience with SBRT, including in patients with poor respiratory function, interstitial pneumonitis (IP), and recurrence after surgery. They considered that the reason for the high incidence of FRP included patient background and large volumes of lung parenchyma irradiated at high doses.^[@bibr4-1533033818801323]^ Timmerman *et al* ^[@bibr5-1533033818801323]^ reported a higher incidence of FRP after SBRT in tumors that were located more centrally. Hope *et al* ^[@bibr6-1533033818801323]^ and Matsuo *et al* ^[@bibr7-1533033818801323]^ found that FRP occurrence is correlated with the volume of the higher dose region; although, Takeda *et al* ^[@bibr8-1533033818801323]^ claimed that severe radiation pneumonitis post-SBRT for lung cancer was not related to lung dose.

Concerning the relationship with patient background in the development of FRP in this study, it is notable that more than half (63%) of patients who experienced FRP had CT findings of IP. Interstitial pneumonitis is considered a critical potential complication following surgery, chemotherapy, or radiotherapy for lung malignancies.^[@bibr9-1533033818801323]^ Takeda *et al* ^[@bibr10-1533033818801323]^ reported acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by SBRT in a patient with slight focal honeycomb changes of the lung, and argued that attention must be paid to the presence of comorbid IP even if minimal. [Table 3](#table3-1533033818801323){ref-type="table"} summarizes the incidences of severe radiation pneumonitis categorized based on whether they were accompanied by pulmonary interstitial changes after SBRT for lung cancer.^[@bibr7-1533033818801323],[@bibr11-1533033818801323][@bibr12-1533033818801323][@bibr13-1533033818801323]--[@bibr14-1533033818801323]^ Grade 3 or higher radiation pneumonitis was observed in 10% to 40% of patients with pulmonary interstitial changes; grade 5 was observed in more than 5% of such patients. These rates may even be higher in prospective settings.

###### 

Frequency of Radiation Pneumonitis Post-SBRT for Lung Cancer According to Presence of Pulmonary Interstitial Change.

![](10.1177_1533033818801323-table3)

  Pulmonary Interstitial Change                    Author (Ref)                                     Study Design       Patient Number    Dose/Fraction   Grade of Radiation Pneumonitis   Frequency            Risk Factor
  ------------------------------------------------ ------------------------------------------------ ------------------ ----------------- --------------- -------------------------------- -------------------- -------------
  No pulmonary interstitial change                 Matsuo *et al* ^[@bibr7-1533033818801323]^       Retrospective      74                48 Gy/4 fr      3                                10.6%                V25
  4                                                1.9%                                                                                                                                                        
  Nagata *et al* ^[@bibr11-1533033818801323]^      Prospective                                      104 (inoperable)   48 Gy/4 fr        3               6.2%                                                  
  65 (operable)                                    48 Gy/4 fr                                       3                  3.6%                                                                                    
  Yamaguchi *et al* ^[@bibr12-1533033818801323]^   Retrospective                                    86                 48 Gy/4 fr        4-5             0.0%                                                  
  Ueki *et al* ^[@bibr13-1533033818801323]^        Retrospective                                    137                48-60 Gy/4-8 fr   3-5             1.4%                                                  
  Yoshitake *et al* ^[@bibr14-1533033818801323]^   Retrospective                                    242                48 Gy/4 fr        3               1.2%                                                  
                                                                                                    4-5                0.0%                                                                                    
  With pulmonaryinterstitial change                Yamaguchi *et al* ^[@bibr12-1533033818801323]^   Retrospective      16                48 Gy/4 fr      3                                6.3%                 V5-25, MLD
  4                                                6.3%                                                                                                                                                        
  5                                                6.3%                                                                                                                                                        
  Ueki *et al* ^[@bibr13-1533033818801323]^        Retrospective                                    20                 40-60Gy/4-8 fr    3-5             10.0%                                                 
  Yoshitake *et al* ^[@bibr14-1533033818801323]^   Retrospective                                    18                 48 Gy/4 fr        3               16.7%                            KL-6, V5, V10, MLD   
  4-5                                              22.3%                                                                                                                                                       

Abbreviations: KL-6, Krebs von den Lungen-6; MLD, mean dose of normal lung; SBRT, stereotactic body radiation therapy

As for other risk factors, Kong *et al* ^[@bibr15-1533033818801323]^ reported that blood biomarkers such as transforming growth factor (TGF)- β1, interleukin-6, KL-6, surfactant proteins, and interleukin-1 receptor agonist could accurately predict radiation-induced lung damage. In this study, KL-6 was abnormally high in more than 70% of the cases. Additionally, other studies have shown a relationship between the severity of radiation pneumonitis and various genetic variations or polymorphisms in microRNA-related genes,^[@bibr16-1533033818801323]^ vascular endothelial growth factor,^[@bibr17-1533033818801323]^ and TGF-β1.^[@bibr18-1533033818801323]^ Notably, 7 of 19 patients with FRP had no IP detected on CT. Coexisting heart disease might be possibly another important risk factor for FRP; however, the incidences of heart failure should be investigated in patients with no severe FRP outbreaks for comparison. To our knowledge, no published studies exist on the relationship between radiation pneumonitis and coexisting heart disease. However, the existence of such a relationship, as well as between radiation pneumonitis and other possible risk factors, is very much worth investigating. Our data suggest that patients with risk factors such as pulmonary interstitial change or coexisting heart disease would be better to receive special attention following SBRT; such individuals may require higher dose-concentrated methods and should be monitored carefully after SBRT. Ebara *et al* ^[@bibr19-1533033818801323]^ reported that particle therapy may be useful for sparing the background lung from high radiation doses.

There were some limitations in our study. First, we could not definitely show the true proportion of patients with FRP in all patients because this was just a retrospective case series study.

Second, particular risk factors of FRP were not examined because we had no comparison of the factors between the 2 groups, with or without FRP. We remarked that coexisting pulmonary interstitial change and heart disease are major risk factors in this study; however, these remain to be confirmed. Therefore, we will further examine these issues in case--control or prospective studies; in addition to this, we aim to obtain serum or tissue for key genetic factors or inflammatory mediators, in future.

In summary, the survival intervals following the appearance of pneumonia symptoms in 23 patients who developed FRP after SBRT for lung cancer were generally short but exhibited a wide range. More than half of the patients had pulmonary fibrosis on CT before SBRT, although immediately progressive FRP was also observed among patients without such pulmonary interstitial change. Coexisting heart disease might possibly exacerbate radiation pneumonitis. Further prospective study with a large cohort is mandatory to confirm it by a comparison of these factors between patient cohorts with or without them.
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